Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease

Takeru Asano; Ken Ichi Matsuoka; Satoshi Iyama; Kazuteru Ohashi; Yoshihiro Inamoto; Chikako Ohwada; Makoto Murata; Atsushi Satake; Chikamasa Yoshida; Koichi Nakase; Yasuo Mori; Mitsune Tanimoto

Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease

Takeru Asano
, Ken Ichi Matsuoka
, Satoshi Iyama
, Kazuteru Ohashi
, Yoshihiro Inamoto
, Chikako Ohwada
, Makoto Murata
, Atsushi Satake
, Chikamasa Yoshida
, Koichi Nakase
, Yasuo Mori
, Mitsune Tanimoto

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

抄録

Chronic graft versus host disease (cGVHD) remains a major problem for long survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Currently, corticosteroid therapy is effective for cGVHD as the first line therapy. However, prolonged therapy with corticosteroids causes various severe adverse events. To develop the new therapeutic strategy of cGVHD, we have launched a multicenter phase I/IIa clinical trial of low dose subcutaneous interleukin-2 (IL-2) for treatment of steroid refractory cGVHD, which is constituted of 2 sequential phases (induction phase and maitanance phase). This study will provide the new therapeutic option for patients with refractory cGVHD after allogeneic HSCT.

本文言語	英語
ページ（範囲）	429-433
ページ数	5
ジャーナル	Acta Medica Okayama
巻	70
号	5
出版ステータス	出版済み - 2016
外部発表	はい

All Science Journal Classification (ASJC) codes

生化学、遺伝学、分子生物学一般

他のファイルとリンク

フィンガープリント

「Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

@article{7e28c0a3da7e4eb1bd65ae2257480bb5,

title = "Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease",

abstract = "Chronic graft versus host disease (cGVHD) remains a major problem for long survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Currently, corticosteroid therapy is effective for cGVHD as the first line therapy. However, prolonged therapy with corticosteroids causes various severe adverse events. To develop the new therapeutic strategy of cGVHD, we have launched a multicenter phase I/IIa clinical trial of low dose subcutaneous interleukin-2 (IL-2) for treatment of steroid refractory cGVHD, which is constituted of 2 sequential phases (induction phase and maitanance phase). This study will provide the new therapeutic option for patients with refractory cGVHD after allogeneic HSCT.",

author = "Takeru Asano and Matsuoka, \{Ken Ichi\} and Satoshi Iyama and Kazuteru Ohashi and Yoshihiro Inamoto and Chikako Ohwada and Makoto Murata and Atsushi Satake and Chikamasa Yoshida and Koichi Nakase and Yasuo Mori and Mitsune Tanimoto",

note = "Publisher Copyright: {\textcopyright} 2016 by Okayama University Medical School.",

year = "2016",

language = "English",

volume = "70",

pages = "429--433",

journal = "Acta Medica Okayama",

issn = "0386-300X",

publisher = "Okayama University",

number = "5",

}

TY - JOUR

T1 - Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease

AU - Asano, Takeru

AU - Matsuoka, Ken Ichi

AU - Iyama, Satoshi

AU - Ohashi, Kazuteru

AU - Inamoto, Yoshihiro

AU - Ohwada, Chikako

AU - Murata, Makoto

AU - Satake, Atsushi

AU - Yoshida, Chikamasa

AU - Nakase, Koichi

AU - Mori, Yasuo

AU - Tanimoto, Mitsune

PY - 2016

Y1 - 2016

N2 - Chronic graft versus host disease (cGVHD) remains a major problem for long survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Currently, corticosteroid therapy is effective for cGVHD as the first line therapy. However, prolonged therapy with corticosteroids causes various severe adverse events. To develop the new therapeutic strategy of cGVHD, we have launched a multicenter phase I/IIa clinical trial of low dose subcutaneous interleukin-2 (IL-2) for treatment of steroid refractory cGVHD, which is constituted of 2 sequential phases (induction phase and maitanance phase). This study will provide the new therapeutic option for patients with refractory cGVHD after allogeneic HSCT.

AB - Chronic graft versus host disease (cGVHD) remains a major problem for long survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Currently, corticosteroid therapy is effective for cGVHD as the first line therapy. However, prolonged therapy with corticosteroids causes various severe adverse events. To develop the new therapeutic strategy of cGVHD, we have launched a multicenter phase I/IIa clinical trial of low dose subcutaneous interleukin-2 (IL-2) for treatment of steroid refractory cGVHD, which is constituted of 2 sequential phases (induction phase and maitanance phase). This study will provide the new therapeutic option for patients with refractory cGVHD after allogeneic HSCT.

UR - https://www.scopus.com/pages/publications/84997706260

UR - https://www.scopus.com/pages/publications/84997706260#tab=citedBy

M3 - Article

C2 - 27777442

AN - SCOPUS:84997706260

SN - 0386-300X

VL - 70

SP - 429

EP - 433

JO - Acta Medica Okayama

JF - Acta Medica Okayama

IS - 5

ER -